SANDOZ AMBRISENTAN 10 MG
AMBRISENTAN : 10 MG · DIN 02525313 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED PRE MARKET
What is SANDOZ AMBRISENTAN?
SANDOZ AMBRISENTAN 10 MG contains AMBRISENTAN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02525313, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 26-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02525313 |
|---|---|
| Brand name | SANDOZ AMBRISENTAN |
| Generic / active ingredient | AMBRISENTAN : 10 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C02KX02 AMBRISENTAN |
| AHFS class | 48:48.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 26-Jul-2023 |
What can be used instead?
Other Canadian products sharing ATC code C02KX02 AMBRISENTAN. 4 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-AMBRISENTAN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02475383 |
| APO-AMBRISENTAN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02475375 |
| VOLIBRIS | 10 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02307073 |
| VOLIBRIS | 5 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02307065 |
| AURO-AMBRISENTAN | 10 MG | TABLET | AURO PHARMA INC | APPROVED | DIN 02527103 |
| AURO-AMBRISENTAN | 5 MG | TABLET | AURO PHARMA INC | APPROVED | DIN 02527081 |
| JAMP AMBRISENTAN | 10 MG | TABLET | JAMP PHARMA CORPORATION | DORMANT | DIN 02521946 |
| JAMP AMBRISENTAN | 5 MG | TABLET | JAMP PHARMA CORPORATION | DORMANT | DIN 02521938 |
| M-AMBRISENTAN | 10 MG | TABLET | MANTRA PHARMA INC | APPROVED | DIN 02554097 |
| M-AMBRISENTAN | 5 MG | TABLET | MANTRA PHARMA INC | APPROVED | DIN 02554089 |
Who else supplies AMBRISENTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMBRISENTAN appears in 171 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.